Atherosclerosis

What Is Atherosclerosis?

Atherosclerosis is a chronic condition marked by the gradual buildup of fatty deposits, inflammatory cells, and fibrous tissue within the walls of arteries, progressively narrowing these vessels and impairing normal blood flow over time.

Long before atherosclerosis produces any noticeable symptoms, it exists in what is known as a subclinical stage, characterized by endothelial dysfunction, oxidative stress, increased arterial stiffness, and disrupted signaling among various inflammatory cells and proteins circulating in the blood.¹

Because this early, subclinical stage develops silently, researchers have increasingly focused on noninvasive detection methods, including arterial stiffness measurement and imaging of the carotid artery wall, to identify at risk individuals well before symptoms or complications ever appear.¹

Subclinical atherosclerosis is characterized by endothelial dysfunction, oxidative stress related abnormalities, increased arterial stiffness, increased apoptosis, and dysregulation of cytokines and adipokines.
National Center for Biotechnology Information

Symptoms

Atherosclerosis typically produces no symptoms during its early, subclinical stage, which can persist for years or even decades before any clinical signs become apparent.

As arterial narrowing becomes more significant, symptoms tend to reflect whichever artery is most affected, such as chest discomfort during exertion when coronary arteries are involved, or leg pain during walking when arteries in the limbs are affected.

Sudden, severe symptoms can occur if a plaque becomes unstable and ruptures, triggering an acute event such as a heart attack or stroke, depending on the specific artery involved.

Causes

Atherosclerosis begins with dysfunction of the endothelium, the delicate inner lining of blood vessels, setting off a cascade of inflammatory changes that ultimately drive plaque formation within the artery wall.¹

Circulating inflammatory markers and proteins, including fibrinogen, C-reactive protein, and various signaling molecules released by fat tissue, actively participate in this process, contributing to the progression of subclinical disease toward more advanced, clinically significant atherosclerosis.¹

Because single biomarkers tend to fluctuate considerably over time and lack strong predictive power on their own, researchers increasingly rely on composite biomarker panels that combine multiple inflammatory and clotting related markers to better capture the ongoing, chronic nature of the disease process.¹

Risk Factors

Chronic inflammatory conditions, including systemic lupus erythematosus and psoriasis, have been associated with accelerated subclinical atherosclerosis, reflecting how systemic inflammation extends its influence well beyond the specific organs primarily affected by these conditions.¹

Insulin resistance has also been linked to early markers of endothelial dysfunction and subclinical atherosclerosis, suggesting that metabolic disturbances can be detected affecting blood vessel health even before diabetes itself is diagnosed.¹

Obesity contributes meaningfully to subclinical atherosclerosis risk as well, with noninvasive testing methods, including arterial stiffness measurement and carotid imaging, increasingly used to evaluate cardiovascular risk in this population before symptoms develop.¹

Complications

As atherosclerotic plaque accumulates and narrows affected arteries, blood flow to downstream tissues becomes progressively compromised, setting the stage for both chronic, exertion related symptoms and sudden, acute events.

Plaque rupture represents one of the most dangerous complications of atherosclerosis, since the sudden formation of a blood clot at the rupture site can abruptly and completely block blood flow through the affected artery.

Because atherosclerosis frequently develops throughout multiple arteries simultaneously rather than in isolation, patients with clinically apparent disease in one location often harbor significant, still silent disease elsewhere in their arterial system.

Treatment

Statin therapy remains the foundation of atherosclerosis treatment, though for patients at high cardiovascular risk who do not achieve adequate cholesterol reduction with statins alone, ezetimibe offers a well tolerated way to further lower LDL cholesterol and reduce cardiovascular risk.²

For patients who remain above target cholesterol levels despite maximum tolerated statin therapy combined with ezetimibe, PCSK9 inhibitors represent a further treatment option, and when combined with statins, this combination has been shown to meaningfully reduce heart attack and stroke risk among high risk patients.²

Combination therapy appears to provide the greatest benefit specifically among patients at high cardiovascular risk, since research suggests that adding these additional medications provides little meaningful benefit for patients whose baseline cardiovascular risk is only low or moderate.²

Prevention

Because subclinical atherosclerosis can be identified through noninvasive testing well before symptoms develop, earlier risk assessment allows for more proactive prevention strategies among people found to be at elevated risk.¹

Managing chronic inflammatory conditions and metabolic disturbances, including insulin resistance, plays an important preventive role, given their demonstrated association with accelerated subclinical disease progression.¹

For patients already identified as high risk, appropriately intensive lipid lowering therapy, guided by individual risk level rather than a uniform approach, offers the most effective strategy for preventing progression toward major cardiovascular events.²

Why Visual Communication Matters for Atherosclerosis

Explaining how atherosclerosis can be detected years before symptoms appear, through subtle changes in blood vessel function and circulating biomarkers, requires visuals that make this invisible early disease stage concrete and motivating.

Pharmaceutical companies, cardiology practices, and patient education organizations rely on clear illustration and animation to explain atherosclerosis biology and support meaningful engagement with early detection and treatment.

• Illustrating endothelial dysfunction and the earliest, subclinical stages of disease
• Animating how composite biomarkers and imaging detect disease before symptoms appear
• Explaining the mechanism of action of statins, ezetimibe, and PCSK9 inhibitors
• Visualizing plaque rupture and its connection to heart attack and stroke
• Supporting patient education on risk based, individualized treatment approaches
• Creating training materials for cardiology and preventive medicine clinicians

How Biotic Artlab Supports Atherosclerosis Communication

We work with pharmaceutical companies, cardiology practices, and patient advocacy organizations to create accurate, engaging visuals that make atherosclerosis and its management easier to understand.

• Custom 3D animations of endothelial dysfunction and early plaque formation
• Detailed illustrations of noninvasive detection methods including carotid imaging
• Mechanism of action animations for statins, ezetimibe, and PCSK9 inhibitors
• Patient facing materials on risk based prevention and treatment strategies
• Clinical training content for cardiology and preventive medicine teams
• Conference presentations and marketing visuals for cardiovascular health audiences

Frequently Asked Questions

Can atherosclerosis be detected before symptoms appear?

Yes, noninvasive testing including arterial stiffness measurement and carotid imaging can identify subclinical atherosclerosis years before symptoms develop.¹

What causes atherosclerosis to progress?

Endothelial dysfunction combined with ongoing inflammation and abnormal biomarker signaling drives the gradual progression from subclinical to clinically significant disease.¹

Who benefits most from combination lipid lowering therapy?

Patients at high cardiovascular risk see the greatest benefit from combining statins with ezetimibe or PCSK9 inhibitors, while lower risk patients see little added benefit.²

Are chronic inflammatory conditions linked to atherosclerosis?

Yes, conditions such as lupus and psoriasis have been associated with accelerated subclinical atherosclerosis due to their systemic inflammatory effects.¹

What is a PCSK9 inhibitor?

PCSK9 inhibitors are medications that further lower LDL cholesterol beyond statins alone, reducing cardiovascular events in appropriately selected high risk patients.²

Does insulin resistance affect atherosclerosis risk?

Yes, insulin resistance has been linked to early markers of endothelial dysfunction and subclinical atherosclerosis, even before diabetes is diagnosed.¹

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to atherosclerosis or cardiovascular health, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information. Evaluation of Subclinical Atherosclerosis in Obese Patients With Three Noninvasive Methods.
2. National Center for Biotechnology Information. PCSK9 Inhibitors and Ezetimibe With or Without Statin Therapy for Cardiovascular Risk Reduction, A Systematic Review and Network Meta Analysis.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, emergency care, or individualized advice from a qualified healthcare professional.